347 related articles for article (PubMed ID: 14751402)
1. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
Liston DR; Nielsen JA; Villalobos A; Chapin D; Jones SB; Hubbard ST; Shalaby IA; Ramirez A; Nason D; White WF
Eur J Pharmacol; 2004 Feb; 486(1):9-17. PubMed ID: 14751402
[TBL] [Abstract][Full Text] [Related]
2. A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066.
Snape MF; Misra A; Murray TK; De Souza RJ; Williams JL; Cross AJ; Green AR
Neuropharmacology; 1999 Jan; 38(1):181-93. PubMed ID: 10193909
[TBL] [Abstract][Full Text] [Related]
3. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):609-13. PubMed ID: 11256231
[TBL] [Abstract][Full Text] [Related]
4. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
5. N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine.
Cerbai F; Giovannini MG; Melani C; Enz A; Pepeu G
Eur J Pharmacol; 2007 Oct; 572(2-3):142-50. PubMed ID: 17643410
[TBL] [Abstract][Full Text] [Related]
6. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine.
Zhao Q; Tang XC
Eur J Pharmacol; 2002 Nov; 455(2-3):101-7. PubMed ID: 12445575
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of cholinesterase inhibitors in Alzheimer's disease.
HÃ¥kansson L
Acta Neurol Scand Suppl; 1993; 149():7-9. PubMed ID: 7907455
[TBL] [Abstract][Full Text] [Related]
8. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Rakonczay Z
Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
[TBL] [Abstract][Full Text] [Related]
9. Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat.
Dronfield S; Egan K; Marsden CA; Green AR
J Psychopharmacol; 2000; 14(3):275-9. PubMed ID: 11106308
[TBL] [Abstract][Full Text] [Related]
10. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats.
Kosasa T; Kuriya Y; Matsui K; Yamanishi Y
Eur J Pharmacol; 1999 Sep; 380(2-3):101-7. PubMed ID: 10513568
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats.
Kosasa T; Kuriya Y; Matsui K; Yamanishi Y
Eur J Pharmacol; 2000 Feb; 389(2-3):173-9. PubMed ID: 10688981
[TBL] [Abstract][Full Text] [Related]
12. Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats.
Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
Eur J Pharmacol; 2001 Mar; 415(2-3):157-64. PubMed ID: 11274994
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Shao D; Zou C; Luo C; Tang X; Li Y
Bioorg Med Chem Lett; 2004 Sep; 14(18):4639-42. PubMed ID: 15324879
[TBL] [Abstract][Full Text] [Related]
15. 7-MEOTA-donepezil like compounds as cholinesterase inhibitors: Synthesis, pharmacological evaluation, molecular modeling and QSAR studies.
Korabecny J; Dolezal R; Cabelova P; Horova A; Hruba E; Ricny J; Sedlacek L; Nepovimova E; Spilovska K; Andrs M; Musilek K; Opletalova V; Sepsova V; Ripova D; Kuca K
Eur J Med Chem; 2014 Jul; 82():426-38. PubMed ID: 24929293
[TBL] [Abstract][Full Text] [Related]
16. Huperzine A, a novel promising acetylcholinesterase inhibitor.
Cheng DH; Ren H; Tang XC
Neuroreport; 1996 Dec; 8(1):97-101. PubMed ID: 9051760
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Darreh-Shori T; Hosseini SM; Nordberg A
J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
[TBL] [Abstract][Full Text] [Related]
18. Effects of T-82, a new quinoline derivative, on cholinesterase activity and extracellular acetylcholine concentration in rat brain.
Isoma K; Ishikawa M; Ohta M; Ogawa Y; Hasegawa H; Kohda T; Kamei J
Jpn J Pharmacol; 2002 Feb; 88(2):206-12. PubMed ID: 11928722
[TBL] [Abstract][Full Text] [Related]
19. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.
Sugimoto H; Ogura H; Arai Y; Limura Y; Yamanishi Y
Jpn J Pharmacol; 2002 May; 89(1):7-20. PubMed ID: 12083745
[TBL] [Abstract][Full Text] [Related]
20. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Nordberg A; Svensson AL
Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]